Bolt Biotherapeutics, Inc. Operating Lease, Liability, Current
Bolt Biotherapeutics, Inc. (BOLT) had Operating Lease, Liability, Current of $3.09 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-11
- 2026-06-30: Operating Lease, Liability, Current $3.09M.
- 2026-03-31: Operating Lease, Liability, Current $2.96M.
- 2025-12-31: Operating Lease, Liability, Current $2.83M.
- 2025-09-30: Operating Lease, Liability, Current $2.70M.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $3.09M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $2.96M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $2.83M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $2.70M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $2.56M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $2.40M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $2.25M 10-K · filed 2026-03-12 |
| 2024-09-30 | $2.82M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $3.00M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $2.89M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $2.78M 10-K · filed 2025-03-24 |
| 2023-09-30 | $2.68M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $2.58M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $2.48M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $2.39M 10-K · filed 2024-03-21 |
| 2022-09-30 | $2.38M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $2.15M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $2.06M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $2.50M 10-K · filed 2023-03-29 |
| 2021-09-30 | $2.41M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $2.32M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $1.63M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $1.50M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |